Among patients developing TB while using anti-TNF agents, 46.8% had pulmonary involvement and 53.2% had extra-pulmonary involvement including lymphadenitis TB, military TB, peritoneal TB, intestinal TB and bone TB). The gene discussed is TNF; the disease is tuberculosis.